• ACEi/ARB impact on mortality in COVID-19 patients with concomitant hypertension • Retrospective, multi-centre cohort study
• Patients with comorbid hypertension hospitalized with COVID-19
• Age 18 to 74 years
• Primary endpoint of 28-day all-cause mortality
•  N = 188 ACEi/ARB therapy
•  N = 940 no ACEi/ARB • ACEi/ARB for treatment of hypertension
• individual patient dosing regimens not specified • Risk of all-cause mortality lower in ACEi/ARB treated group HR 0.42 (95% CI 0.19–0.92).
• Use of ACEi/ARB in comparison to other anti-hypertension therapies was associated with lower mortality HR 0.30 (95% CI 0.12–0.70).
• No difference in acute cardiac injury outcome between groups • Chronic ACEi/ARB therapy may not increase mortality of COVID-19 patients
• May not have much benefit in acute heart injury due to COVID-19 inflammation (Zhang, Zhu, Cai, et al., 2020)